Oxford BioDynamics Plc (OXBOF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Oxford BioDynamics Plc (OXBOF) es una empresa del sector Healthcare valorada en 0. Calificado con 49/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 17 mar 2026Oxford BioDynamics Plc (OXBOF) Resumen de Asistencia Médica y Tuberías
Oxford BioDynamics Plc leverages its EpiSwitch platform to discover and develop epigenetic biomarkers for disease prediction and treatment. The company operates in the biotechnology sector, offering diagnostic and prognostic tools like EpiSwitch CiRT and CST, primarily targeting the pharmaceutical and biotechnology industries internationally.
Tesis de Inversión
Oxford BioDynamics presents a high-risk, high-reward investment profile within the biotechnology sector. The company's proprietary EpiSwitch platform offers a unique approach to biomarker discovery with potential applications across various diseases. A key value driver is the successful commercialization of EpiSwitch CiRT, which could generate revenue through predicting patient response to immunotherapy. The company's ability to secure partnerships with pharmaceutical companies for biomarker discovery and drug development is also crucial. However, the company's negative profit and gross margins (-1018.5% and -561.6%, respectively) highlight financial challenges. Upcoming data releases from clinical studies using EpiSwitch and regulatory approvals for its diagnostic tests are potential catalysts. Investors should closely monitor the company's cash burn rate and ability to secure additional funding to sustain operations.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- EpiSwitch Platform: Proprietary technology for epigenetic biomarker discovery.
- EpiSwitch CiRT: Validated prognostic test for predicting response to checkpoint inhibitor immunotherapy.
- EpiSwitch CST: Advanced blood test for predicting COVID-19 severity in adults.
- Market Cap: $0.00B indicates the company is a micro-cap stock.
- Negative Profit Margin: -1018.5% signals significant losses and operational inefficiencies.
Competidores y Pares
Fortalezas
- Proprietary EpiSwitch platform for epigenetic biomarker discovery.
- Validated diagnostic tests like EpiSwitch CiRT and CST.
- Expertise in epigenetics and biomarker development.
- Potential for partnerships with pharmaceutical companies.
Debilidades
- Negative profit and gross margins.
- Limited commercialization of products.
- Dependence on external funding.
- OTC market listing indicates higher risk.
Catalizadores
- Upcoming: Data releases from clinical studies using EpiSwitch for biomarker discovery.
- Upcoming: Potential regulatory approvals for EpiSwitch CiRT and other diagnostic tests.
- Ongoing: Expansion of partnerships with pharmaceutical companies for drug development.
- Ongoing: Increasing adoption of EpiSwitch technology in personalized medicine.
- Ongoing: Development of new diagnostic tests for autoimmune diseases.
Riesgos
- Ongoing: Negative profit and gross margins raise concerns about financial sustainability.
- Potential: Competition from established players in genomics and proteomics.
- Potential: Regulatory hurdles for diagnostic tests.
- Potential: Failure to secure additional funding.
- Ongoing: Limited liquidity due to OTC market listing.
Oportunidades de crecimiento
- Expansion of EpiSwitch CiRT into new cancer types: The EpiSwitch CiRT test is currently focused on predicting response to checkpoint inhibitors in specific cancers. Expanding its application to other cancer types represents a significant growth opportunity. The global oncology market is projected to reach $286.6 billion by 2028, providing a large addressable market for CiRT and future diagnostic tests. Timeline: Ongoing clinical trials and validation studies are expected to support expansion over the next 2-3 years.
- Development of new diagnostic tests for autoimmune diseases: Autoimmune diseases represent a significant unmet medical need, and the EpiSwitch platform could be used to develop novel diagnostic tests. The global autoimmune disease diagnostics market is projected to reach $16.1 billion by 2027. Oxford BioDynamics could leverage its technology to capture a share of this market. Timeline: Research and development efforts are likely to span 3-5 years before a commercially viable product is available.
- Partnerships with pharmaceutical companies for drug development: Oxford BioDynamics can partner with pharmaceutical companies to use the EpiSwitch platform to identify biomarkers for drug development. This could generate revenue through licensing agreements, milestone payments, and royalties on sales of drugs developed using the company's biomarkers. The pharmaceutical industry spends billions of dollars annually on drug discovery and development, creating a substantial market for biomarker-based services. Timeline: Partnership agreements could be established within the next 1-2 years, with revenue generation dependent on the success of drug development programs.
- Geographic expansion into Asia and Europe: Oxford BioDynamics currently focuses on the United States and international markets. Expanding into Asia and Europe represents a growth opportunity, particularly in countries with advanced healthcare systems and a growing demand for personalized medicine. The Asia-Pacific diagnostics market is projected to be the fastest-growing region globally. Timeline: Expansion efforts could begin within the next 2 years, with a focus on establishing partnerships and distribution networks.
- Application of EpiSwitch technology to personalized medicine: The EpiSwitch platform can be used to develop personalized medicine approaches, tailoring treatment decisions to individual patients based on their epigenetic profiles. The personalized medicine market is growing rapidly, driven by advances in genomics and proteomics. Oxford BioDynamics can position itself as a leader in epigenetic-based personalized medicine. Timeline: Development of personalized medicine applications is a long-term effort, likely to span 5-10 years.
Oportunidades
- Expansion of EpiSwitch CiRT into new cancer types.
- Development of new diagnostic tests for autoimmune diseases.
- Partnerships with pharmaceutical companies for drug development.
- Geographic expansion into Asia and Europe.
Amenazas
- Competition from established players in genomics and proteomics.
- Regulatory hurdles for diagnostic tests.
- Failure to secure additional funding.
- Uncertainty in the biotechnology industry.
Ventajas competitivas
- Proprietary EpiSwitch platform: Provides a unique technology for epigenetic biomarker discovery.
- Validated diagnostic tests: EpiSwitch CiRT and CST have demonstrated clinical utility.
- Expertise in epigenetics: Oxford BioDynamics has a team of scientists with expertise in epigenetics and biomarker discovery.
- Partnerships with pharmaceutical companies: Provides access to resources and expertise for drug development.
Acerca de OXBOF
Oxford BioDynamics Plc, incorporated in 2007 and headquartered in Oxford, UK, is a biotechnology company specializing in the discovery and development of biomarkers. The company's core technology is EpiSwitch, a proprietary platform that identifies and validates chromosome conformation signatures for use as epigenetic biomarkers. These biomarkers are applied in medical testing kits, disease prediction, diagnosis, and treatment monitoring. The company's key products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a prognostic test designed to predict a patient's response to checkpoint inhibitor immunotherapy. Another product, EpiSwitch CST (Covid Severity Test), is a blood test aimed at predicting the severity of COVID-19 in adults. Additionally, Oxford BioDynamics offers the EpiSwitch Explorer Array Kit, which facilitates high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics primarily serves the pharmaceutical and biotechnology industries, focusing on developing tools that can improve drug development, clinical trials, and patient outcomes. The company operates both in the United States and internationally, seeking partnerships and collaborations to expand the reach of its EpiSwitch technology and biomarker portfolio.
Qué hacen
- Discovers epigenetic biomarkers using its proprietary EpiSwitch platform.
- Develops diagnostic and prognostic tests for various diseases.
- Offers the EpiSwitch CiRT test to predict response to cancer immunotherapy.
- Provides the EpiSwitch CST test for predicting COVID-19 severity.
- Offers the EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling.
- Partners with pharmaceutical companies for biomarker discovery and drug development.
Modelo de Negocio
- Generates revenue through the sale of diagnostic and prognostic tests.
- Partners with pharmaceutical companies for biomarker discovery and drug development, earning licensing fees, milestone payments, and royalties.
- Offers services for high-resolution 3D genome profiling and biomarker discovery using the EpiSwitch Explorer Array Kit.
Contexto de la Industria
Oxford BioDynamics operates within the competitive biotechnology industry, which is characterized by rapid innovation and high regulatory hurdles. The market for biomarker discovery and diagnostics is growing, driven by the increasing demand for personalized medicine and targeted therapies. Companies like Oxford BioDynamics face competition from established players in genomics and proteomics, as well as other emerging biotechnology firms. The company's success depends on its ability to differentiate its EpiSwitch platform, secure regulatory approvals, and establish partnerships with pharmaceutical companies.
Clientes Clave
- Pharmaceutical companies seeking biomarkers for drug development.
- Biotechnology companies developing diagnostic and therapeutic products.
- Hospitals and clinics using diagnostic tests for patient care.
- Research institutions conducting studies on epigenetics and disease.
Finanzas
Gráfico e información
Precio de la acción de Oxford BioDynamics Plc (OXBOF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para OXBOF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para OXBOF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para OXBOF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de OXBOF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Liderazgo: Iain Gladstone Ross
Managing Director
Iain Gladstone Ross serves as the Managing Director of Oxford BioDynamics Plc, overseeing the company's operations and strategic direction. Information regarding his detailed career history and educational background is not available in the provided data. However, as Managing Director, he is responsible for guiding the company's biomarker discovery and diagnostic development efforts.
Historial: As Managing Director, Iain Gladstone Ross manages 51 employees. Specific achievements and milestones under his leadership are not detailed in the provided data. His role is crucial in driving the commercialization of the EpiSwitch platform and securing partnerships to advance the company's growth.
Información del mercado OTC de OXBOF
The OTC Other tier, where Oxford BioDynamics trades, represents the lowest tier of the OTC market. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier often have limited financial disclosure requirements and may not meet minimum listing standards. This tier typically includes companies with higher risk profiles, including those that are thinly traded, distressed, or have limited operating history. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure: The lack of publicly available financial reports makes it difficult to assess the company's financial health.
- Low liquidity: Limited trading volume can lead to wider bid-ask spreads and greater price volatility.
- Higher risk of fraud or manipulation: OTC markets are subject to less regulatory oversight than major exchanges.
- Potential for delisting: Failure to meet minimum listing standards could result in delisting from the OTC market.
- Limited access to capital: OTC-listed companies may have difficulty raising capital through public offerings.
- Verify the availability of financial reports and assess the company's financial health.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the liquidity of the stock and the potential for price volatility.
- Review the company's regulatory filings and compliance history.
- Consult with a financial advisor before investing.
- Confirm the legitimacy of the company's operations and assets.
- Proprietary EpiSwitch platform suggests technological innovation.
- Development of diagnostic tests like EpiSwitch CiRT and CST indicates potential for commercialization.
- Partnerships with pharmaceutical companies could validate the company's technology.
- Headquarters in Oxford, UK, a hub for biotechnology research.
- Management team with experience in the biotechnology industry.
OXBOF Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar OXBOF?
Oxford BioDynamics Plc (OXBOF) actualmente tiene una puntuación IA de 49/100, indicando puntuación baja. Fortaleza clave: Proprietary EpiSwitch platform for epigenetic biomarker discovery.. Riesgo principal a monitorear: Ongoing: Negative profit and gross margins raise concerns about financial sustainability.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de OXBOF?
OXBOF actualmente puntúa 49/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de OXBOF?
Los precios de OXBOF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre OXBOF?
La cobertura de analistas para OXBOF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en OXBOF?
Las categorías de riesgo para OXBOF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Negative profit and gross margins raise concerns about financial sustainability.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de OXBOF?
La relación P/E para OXBOF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está OXBOF sobrevalorada o infravalorada?
Determinar si Oxford BioDynamics Plc (OXBOF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de OXBOF?
Oxford BioDynamics Plc (OXBOF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Financial data is limited and may not be up-to-date.
- Analyst consensus is not available.
- OTC market listing indicates higher risk.